Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP)‘s stock had its “buy” rating restated by stock analysts at Maxim Group in a report issued on Tuesday. They currently have a $23.00 price target on the biopharmaceutical company’s stock, up from their prior price target of $21.00. Maxim Group’s target price indicates a potential upside of 114.95% from the company’s current price.

SCMP has been the subject of several other reports. ValuEngine upgraded Sucampo Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, June 23rd. Zacks Investment Research upgraded Sucampo Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 4th. Roth Capital set a $30.00 target price on Sucampo Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, August 3rd. Jefferies Group LLC lowered their target price on Sucampo Pharmaceuticals from $13.00 to $11.00 and set a “hold” rating for the company in a research note on Thursday, May 4th. Finally, TheStreet downgraded Sucampo Pharmaceuticals from a “c+” rating to a “d” rating in a research note on Wednesday, August 2nd. Three analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $17.63.

Shares of Sucampo Pharmaceuticals (NASDAQ:SCMP) traded up 2.39% during mid-day trading on Tuesday, reaching $10.70. The company’s stock had a trading volume of 627,562 shares. The firm has a 50-day moving average of $10.65 and a 200-day moving average of $10.72. The firm’s market capitalization is $494.28 million. Sucampo Pharmaceuticals has a 52 week low of $9.30 and a 52 week high of $17.55.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last announced its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported $0.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.22 by $0.06. The firm had revenue of $59.90 million during the quarter, compared to the consensus estimate of $56.44 million. Sucampo Pharmaceuticals had a positive return on equity of 56.58% and a negative net margin of 61.99%. The firm’s quarterly revenue was up 15.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.24 EPS. Equities research analysts forecast that Sucampo Pharmaceuticals will post $1.02 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This report was originally published by American Banking News and is owned by of American Banking News. If you are reading this report on another site, it was illegally stolen and republished in violation of United States and international copyright laws. The original version of this report can be read at https://www.americanbankingnews.com/2017/08/08/sucampo-pharmaceuticals-inc-scmp-earns-buy-rating-from-maxim-group.html.

In related news, insider Jones W. Bryan purchased 4,700 shares of Sucampo Pharmaceuticals stock in a transaction dated Friday, August 4th. The shares were acquired at an average price of $10.60 per share, with a total value of $49,820.00. Following the completion of the transaction, the insider now owns 4,700 shares of the company’s stock, valued at approximately $49,820. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Company insiders own 4.13% of the company’s stock.

Institutional investors have recently modified their holdings of the company. Louisiana State Employees Retirement System boosted its position in shares of Sucampo Pharmaceuticals by 1.0% in the second quarter. Louisiana State Employees Retirement System now owns 10,200 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 100 shares during the last quarter. First Citizens Bank & Trust Co. bought a new position in shares of Sucampo Pharmaceuticals during the second quarter valued at approximately $116,000. Karp Capital Management Corp bought a new position in shares of Sucampo Pharmaceuticals during the first quarter valued at approximately $119,000. SG Americas Securities LLC boosted its position in shares of Sucampo Pharmaceuticals by 5.6% in the second quarter. SG Americas Securities LLC now owns 11,977 shares of the biopharmaceutical company’s stock valued at $126,000 after buying an additional 631 shares during the last quarter. Finally, Capstone Asset Management Co. boosted its position in shares of Sucampo Pharmaceuticals by 2.1% in the second quarter. Capstone Asset Management Co. now owns 12,360 shares of the biopharmaceutical company’s stock valued at $130,000 after buying an additional 260 shares during the last quarter. 58.20% of the stock is currently owned by institutional investors and hedge funds.

Sucampo Pharmaceuticals Company Profile

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.

Analyst Recommendations for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.